{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:03:18Z","timestamp":1779955398116,"version":"3.53.1"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      To investigate the effects of perioperative\n                      <jats:sup>177<\/jats:sup>\n                      Lutetium (\n                      <jats:sup>177<\/jats:sup>\n                      Lu)-labeled anticarcinoembryonic antigen (CEA)-targeted radionuclide therapy (TRT) on perioperative inflammatory response, intestinal function recovery, pain control, dosimetric safety, and postoperative complications in colorectal cancer surgery patients within a precision oncology framework.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis of 72 patients who underwent elective radical colorectal cancer surgery (January 2022\u2013December 2023). Patients were divided into a TRT group and a control group (36 cases each). The TRT group received\n                      <jats:sup>177<\/jats:sup>\n                      Lu-labetuzumab (1.85 GBq) 48 h preoperatively and a consolidation dose (0.74 GBq) at 24 h postoperatively; the control group received equivalent saline. Perioperative inflammatory markers [C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-\u03b1), white blood cell, neutrophil percentage], intestinal function recovery, visual analogue scale (VAS) pain scores, analgesic medication usage, dosimetric parameters, nutritional indicators, and postoperative complications were compared.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Baseline characteristics were comparable between groups (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &gt; 0.05). Compared with the control group, the TRT group showed significantly lower inflammatory markers on postoperative days 3 and 7 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.05), shorter bowel sound recovery time (18.4 \u00b1 6.7 h vs. 26.8 \u00b1 8.9 h), first flatus time (28.6 \u00b1 9.3 h vs. 42.1 \u00b1 12.7 h), and defecation time (58.7 \u00b1 18.4 h vs. 78.9 \u00b1 22.6 h) (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001). VAS scores at all time points were significantly lower (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001), with reduced analgesic consumption. Tumor-absorbed dose was 32.7 \u00b1 8.4 Gy with critical organ doses within International Commission on Radiological Protection tolerance. No serious radiotoxic adverse reactions occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      In this retrospective exploratory study of imaging-selected colorectal cancer patients, perioperative\n                      <jats:sup>177<\/jats:sup>\n                      Lu-labeled anti-CEA TRT was associated with lower postoperative inflammatory marker levels, faster recovery of intestinal function, reduced analgesic requirements, and an acceptable short-term safety profile. These findings suggest that perioperative TRT may have potential short-term benefits in carefully selected patients, but prospective studies are required before broader clinical adoption.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10849785261450842","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T10:00:26Z","timestamp":1779703226000},"source":"Crossref","is-referenced-by-count":0,"title":["Effects of Perioperative\n                    <sup>177<\/sup>\n                    Lutetium-Labeled Targeted Radionuclide Therapy on Inflammatory Response and Intestinal Recovery in Colorectal Cancer"],"prefix":"10.1177","author":[{"given":"Jianhua","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Operating Room, The People\u2019s Hospital of Danyang, Danyang City, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Huai\u2019an Clinical Medical College of Jiangsu University (Huai\u2019an Hospital of Huai\u2019an City), Huai\u2019an City, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5610-0143","authenticated-orcid":false,"given":"Sai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Anesthesia Perioperative Medical Center, Xi\u2019an People\u2019s Hospital (Xi\u2019an Fourth Hospital), Xi\u2019an City, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133381"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13037-024-00425-9"},{"issue":"8","key":"e_1_3_2_5_1","first-page":"1191","article-title":"Targeted radionuclide therapy of cancer with radiolabeled antibodies: Overview of current experience","volume":"64","author":"Goldenberg DM","year":"2023","unstructured":"4.Goldenberg DM, , Sharkey RM. Targeted radionuclide therapy of cancer with radiolabeled antibodies: Overview of current experience. J Nucl Med 2023;64(8):1191\u20131199.","journal-title":"J Nucl Med"},{"issue":"4","key":"e_1_3_2_6_1","first-page":"1145","article-title":"177Lu-labetuzumab (anti-CEA) in colorectal cancer: Pharmacokinetics, dosimetry, and preliminary clinical outcomes","volume":"49","author":"Sharkey RM","year":"2022","unstructured":"5.Sharkey RM, , Rossi EA, , McBride WJ, et al. 177Lu-labetuzumab (anti-CEA) in colorectal cancer: Pharmacokinetics, dosimetry, and preliminary clinical outcomes. Eur J Nucl Med Mol Imaging 2022;49(4):1145\u20131158.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"e_1_3_2_7_1","first-page":"1892","article-title":"NF-\u03baB pathway suppression by targeted radionuclide therapy attenuates post-surgical inflammatory amplification in gastrointestinal tumors","volume":"15","author":"Zhang J","year":"2025","unstructured":"6.Zhang J, , Liu H, , Wang Y, et al. NF-\u03baB pathway suppression by targeted radionuclide therapy attenuates post-surgical inflammatory amplification in gastrointestinal tumors. Sci Rep 2025;15(1):1892.","journal-title":"Sci Rep"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1287809"},{"issue":"3","key":"e_1_3_2_9_1","first-page":"165","article-title":"Duration and timing of perioperative radionuclide administration in colorectal cancer: A meta-analysis","volume":"37","author":"Yang W","year":"2023","unstructured":"8.Yang W, , Yan S, , Yu F, et al. Duration and timing of perioperative radionuclide administration in colorectal cancer: A meta-analysis. Ann Nucl Med 2023;37(3):165\u2013178.","journal-title":"Ann Nucl Med"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2020.09.001"},{"key":"e_1_3_2_11_1","first-page":"102733","article-title":"Targeted radionuclide exposure influences NF-\u03baB gene expression and TNF-\u03b1 protein levels","volume":"69","author":"Karnina R","year":"2021","unstructured":"10.Karnina R, , Arif SK, , Hatta M, et al. Targeted radionuclide exposure influences NF-\u03baB gene expression and TNF-\u03b1 protein levels. Ann Med Surg (London) 2021;69:102733.","journal-title":"Ann Med Surg (London)"},{"key":"e_1_3_2_12_1","first-page":"1248630","article-title":"Macrophage polarization dynamics following low-dose targeted irradiation","volume":"14","author":"Fernandes Q","year":"2024","unstructured":"11.Fernandes Q, , Inchakalody VP, , Merhi M, et al. Macrophage polarization dynamics following low-dose targeted irradiation. Front Oncol 2024;14:1248630.","journal-title":"Front Oncol"},{"issue":"11","key":"e_1_3_2_13_1","first-page":"3883","article-title":"Anti-inflammatory and immunomodulatory effects of low-dose targeted radionuclide therapy in surgical oncology","volume":"14","author":"Fern\u00e1ndez-Mart\u00ednez A","year":"2025","unstructured":"12.Fern\u00e1ndez-Mart\u00ednez A, , Gonz\u00e1lez Garc\u00eda J, , L\u00f3pez-Picado A. Anti-inflammatory and immunomodulatory effects of low-dose targeted radionuclide therapy in surgical oncology. J Clin Med 2025;14(11):3883.","journal-title":"J Clin Med"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1591359"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06021-5"},{"issue":"1","key":"e_1_3_2_16_1","first-page":"67","article-title":"Efficacy and safety of perioperative immunomodulatory interventions in laparoscopic colorectal surgery: A meta-analysis","volume":"140","author":"Ostovi\u0107 H","year":"2024","unstructured":"15.Ostovi\u0107 H, , \u0160imac B, , Pra\u017eetina M, et al. Efficacy and safety of perioperative immunomodulatory interventions in laparoscopic colorectal surgery: A meta-analysis. Anesth Analg 2024;140(1):67\u201376.","journal-title":"Anesth Analg"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136872"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002548"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113772"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s44158-024-00208-9"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.64719\/pb.4495"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1561956"},{"issue":"1","key":"e_1_3_2_23_1","first-page":"2398","article-title":"GABAergic pathway modulation following targeted irradiation in spinal pain circuitry","volume":"16","author":"Lee JM","year":"2025","unstructured":"22.Lee JM, , An H, , Kang H, et al. GABAergic pathway modulation following targeted irradiation in spinal pain circuitry. Signal Transduct Target Ther 2025;16(1):2398.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073236"},{"issue":"3","key":"e_1_3_2_25_1","first-page":"1062","article-title":"Inflammatory cytokine-driven protein catabolism attenuation through radionuclide-mediated NF-\u03baB modulation","volume":"18","author":"Park JH","year":"2023","unstructured":"24.Park JH, , Lee SK, , Kim YJ, et al. Inflammatory cytokine-driven protein catabolism attenuation through radionuclide-mediated NF-\u03baB modulation. J Dent Sci 2023;18(3):1062\u20131072.","journal-title":"J Dent Sci"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61543-z"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.17371"},{"issue":"15","key":"e_1_3_2_28_1","first-page":"1678","article-title":"Safety profile and dosimetric parameters of 177Lu-labeled antibody therapy in solid tumors: A systematic review","volume":"42","author":"Mao P","year":"2024","unstructured":"27.Mao P, , Zhang Y, , Liu B, et al. Safety profile and dosimetric parameters of 177Lu-labeled antibody therapy in solid tumors: A systematic review. J Clin Oncol 2024;42(15):1678\u20131691.","journal-title":"J Clin Oncol"},{"issue":"7","key":"e_1_3_2_29_1","first-page":"3236","article-title":"177Lu-labeled anti-CEA TRT in colorectal cancer: Disease control, immune activation, and long-term outcomes","volume":"26","author":"Goldenberg DM","year":"2025","unstructured":"28.Goldenberg DM, , Sharkey RM, , Paganelli G, et al. 177Lu-labeled anti-CEA TRT in colorectal cancer: Disease control, immune activation, and long-term outcomes. Int J Mol Sci 2025;26(7):3236.","journal-title":"Int J Mol Sci"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785261450842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10849785261450842","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785261450842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:18:09Z","timestamp":1779952689000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10849785261450842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":28,"alternative-id":["10.1177\/10849785261450842"],"URL":"https:\/\/doi.org\/10.1177\/10849785261450842","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"10849785261450842"}}